Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 19:00:37 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Abliva - More Reasons to Believe

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Abliva - More Reasons to Believe

2021-06-10 09:20:00

Redeye believes current valuation implies a too cautious view of Abliva’s project portfolio. Early evidence and positive regulatory feedback validate the development of lead candidate KL1333 in primary mitochondrial disease, an untapped orphan drug opportunity. A key element to further successful clinical development and hence rerating, in our opinion, is if Abliva can secure additional financing.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/